The tests will expand the company’s Spotlight menu in neurology and endocrinology, and adds to the selection of tests currently available for epilepsy, developmental delay, endocrinology, and mitochondrial disease.

“We are happy to offer another expansion to our test menu in just a month since our last announcement,” stated Brian McKernan, CEO of Courtagen Life Sciences.

“Our rapid development engine enables Courtagen to address the testing needs of our ordering physicians and institutions quickly. We expect to significantly expand our test offerings over the course of 2017.”

The new Spotlight tests will primarily address neuromuscular disorders, such as congenital myasthenia, hereditary spastic paraplegia, congenital and limb-girdle muscular dystrophy, and myopathies, and one new endocrine disorder test for Bardet-Biedl syndrome.

Courtagen Life Sciences is a CLIA/CAP certified endocannabinoid platform and molecular information company focused on the diagnosis of a range of neurological, endocrine, and functional disorders associated with the central, peripheral, and autonomic nervous systems, including the endocannabinoid receptor system.

Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business that helps physicians elucidate the linkages between the genotypes and phenotypes of various diseases, which may be treated with a host of therapies, including pharmaceutical drugs and medical cannabis.